Funding Opportunities

TB Centers of Excellence for Training, Education and Medical Consultation (COE)

CDC plans to establish and fund up to four regionally-assigned Tuberculosis Centers of Excellence (TB COE) to facilitate efforts to prevent, treat, and control TB disease and latent TB infection (LTBI) in the United States (U.S.). The TB COE will focus on two major activities: (1) increasing knowledge, skills, and abilities for TB prevention and control through communication, education, and training activities, and; (2) improving sustainable evidence based TB clinical practices and patient care through the provision of expert medical consultation. The funds available for these core activities will be used to support TB and LTBI communication efforts, training, education, and medical consultation activities.

Funding Organization

Centers for Disease Control and Prevention - NCHHSTP

Closing Date for Applications

September 6th, 2022

For more information, https://www.grants.gov/web/grants/view-opportunity.html?oppId=336618

The Tuberculosis (TB) Elimination Alliance (TEA) is offering Mini-Grants to organizations serving Asian American (AA), Native Hawaiian, and Pacific Islander (NH/PI) communities that are disproportionately impacted by latent TB infection (LTBI) and/or TB. Additional preference is given to organizations currently serving Asian/Asian American (A/AA) and NH/PI populations with an interest in expanding to non-US born Latino American, and US born African American communities.

Mini-Grant proposals must align with TEA’s priority areas and activities that reflect community engagement and education, provider education, and/or quality improvement.

Up to 15 awards will be provided to selected organizations. Each award amount will be between $10,000 and $30,000. Deadline to apply is Friday, August 5 by 5:00pm local time.

For more information please visit, https://tbeliminationalliance.org/2022-2023-tb-elimination-alliance-mini-grant-program-request-for-funding-proposal/

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. Concepts reveal possible initiatives or give you ideas for an investigator-initiated application.

Analyzing Early Events in Tuberculosis (TB) and TB/HIV Infection To Identify Interventional Targets

Request for Applications—proposed FY 2024 initiative

Objective: Early events associated with Mycobacterium tuberculosis (Mtb) infection are not well understood. However, studies delineating the initial stage of Mtb infection may identify unique targets for more effective vaccine adjuvants and immunomodulators, as well as improved biomarkers to advance prevention and therapy of TB. The objectives of this initiative are to better understand how Mtb evades and disrupts host immunity at the earliest stages of infection, and how myeloid (macrophages, dendritic cells, eosinophils), lymphoid (T cells, B cells, innate lymphoid cells) and non-immune cells (alveolar epithelial cells, pneumocytes, vascular) in the airway and lung interact with Mtb and each other. Furthermore, delineating the effects of HIV co-infection on immune mechanisms during early Mtb infection will facilitate the development of effective immune-based interventions for people living with HIV.

Contact: 
Robert Mahon
robert.mahon@nih.gov

Consortium for Design of TB Drug Regimens

Request for Applications—proposed FY 2024 initiative

Objective: To establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models with clinical data and identify the most efficacious combination regimens for future clinical testing to optimize relapse-free TB treatment.

Contact:
Barbara Laughon
blaughon@mail.nih.gov

Mycobacterium tuberculosis Quality Assessment (TBQA) Program

Request for Proposals—proposed FY 2024 initiative

Objective: TBQA will 1) support the ability of laboratories to reliably perform study-specified Mycobacterium tuberculosis (Mtb) tests; 2) evaluate Mtb technologies and specimen processes for use in clinical investigations; 3) disseminate technical and scientific data; 4) perform late-stage assay validation and/or Mtb assay testing of clinical samples in a CLIA-certified laboratory (Option); and 5) support public health emergency needs (Option). The TBQA will serve NIAID-sponsored and collaborating clinical trial networks and cohorts as well as individual grantees conducting research in and outside the United States. Examples of NIAID-sponsored Networks include the Adult AIDS Clinical Trials Group (ACTG), the International Maternal Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT), and the HIV Vaccine Trials Network (HVTN). Examples of NIAID-sponsored TB cohorts include the India and Brazil Regional Prospective Observational Research for Tuberculosis (RePORT).

Contact: 
Isaac Elliott
isaac.elliott@nih.gov

You can find more information here

Open Date (Earliest Submission Date): September 07, 2022

Expiration Date: May 08, 2025

The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.

This Notice also encourages applications to develop once-a-month SR/LA strategies for treatment of latent TB and hepatitis B

https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-042.html?utm…

Notice of Special Interest (NOSI)—Identifying Immune Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection

Notice of Special Interest—proposed FY 2023 initiative

Contact:
Josh Radke
josh.radke@nih.gov

Objective: NIAID has a specific interest in research toward understanding the role cell death mechanisms (CDMs) play in response to Mycobacterium tuberculosis (Mtb) infection, how Mtb subverts cell death pathways to promote infection, and to identify cellular targets that could be exploited as potential host-directed therapies to treat Mtb and Mtb/HIV co-infection.

https://www.niaid.nih.gov/grants-contracts/january-2022-daids-council-approved-concepts#05

Open Date (Earliest Submission Date): May 08, 2022

Expiration Date: June 09, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-015.html

Open Date (Earliest Submission Date): June 08, 2022

Expiration Date: July 09, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-016.html

NIAID 2022 OMNIBUS BROAD AGENCY ANNOUNCEMENT (BAA) NO. HHS-NIH-NIAID-BAA2022-1 contains four (4) distinct Research Areas, each with specified closing date and time.   The proposal due date of March 18, 2022, specified in this solicitation posting, is the due date for Research Area 003 only.  An Amendment will be issued at a later date to update the proposal due date for responses to Research Areas 001, 002, 004.  The proposal due dates for each Research Area are identified below:

Research Area 001 - Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases 

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

Research Area 002 - Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

Research Area 003 - The Antiviral Program for Pandemics (APP): Development of Antivirals for Specific RNA Viral Families of Pandemic Potential

Proposals Due Date and Time - 3:00 PM Eastern Time on March 18, 2022

Research Area 004 - Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections (AMR), and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

For more information click HERE!!

Improved Drug Susceptibility Testing (DST) for Tuberculosis!

Request for Applications—proposed FY 2023 initiative

Objective: To support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point-of-care DST and companion diagnostics for new TB drugs.

Description: This concept would further the development of new diagnostic technologies for TB DST with an emphasis on rapid, point-of-care, low complexity assays. As new drugs move forward in the pipeline, there is a need for companion DST diagnostics for new drugs to ensure new drugs are used most effectively. Current phenotypic methods for determining drug resistance (DR) provide clinically relevant drug susceptibility information but have limitations. For example, the gold standard relies on culture, requires time for growth, and does not provide a result for many days. The program would solicit highly innovative DST assays, including phenotypic DST that may rely on a readout that does not require full growth as in traditional DST assays. Innovative technologies beyond nucleic acid amplification tests will be encouraged. This effort is anticipated to include exploratory work that would further improve our knowledge of genotypic and phenotypic correlates of clinical DR, which can be complex. Research that leverages the rapid advances in diagnostic technologies for COVID-19 applied to TB are also encouraged. Furthermore, this effort would be targeted to technology holders partnered with academic, clinical, and laboratory colleagues with TB diagnostic expertise.

Contact: Karen Lacourciere

lacourcierek@niaid.nih.gov

240-627-3297

Click here for more information!

Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)

Application open date: November 08, 2021

Expiration Date: December 09, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network to advance TB and TB/HIV science. The RePORT Brazil network will leverage and build upon Brazilian cohorts currently following adult and pediatric populations with active TB disease and their contacts or other high TB-risk individuals to address key research questions of regional and global interest. Specific areas supported under this program include, but are not limited to, research and development projects in TB/HIV in the areas of molecular epidemiology, diagnostics, biomarkers, vaccine development, and the impact of co-morbidities such as HIV and diabetes. Research outcomes should be capable of advancing tools with public health impact or of influencing decision making in TB public health to inform stakeholders on the best practices for early prevention, diagnosis, and clinical management of TB and TB/HIV.

Click here for more information about this funding opportunity!